Loading…
Lobbying Spend
—
Filings
4
Firms Hired
1
Active Period
2025–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Skin Substitute Access and Payment Reform Act
2026 · first_quarter · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 5768
Advanced Wound Care and Regenerative Medicine Access and Reform Act
2026 · first_quarter · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.
Client expense: — · Firm income: $20,000
Matched citations: H.R.6852
Skin Substitute Access and Payment Reform Act of 2025
2026 · first_quarter · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.
Client expense: — · Firm income: $20,000
Matched citations: S. 2561
Skin Substitute Access and Payment Reform Act
2025 · fourth_quarter · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 5768
Advanced Wound Care and Regenerative Medicine Access and Reform Act
2025 · fourth_quarter · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.
Client expense: — · Firm income: $50,000
Matched citations: H.R.6852
Skin Substitute Access and Payment Reform Act of 2025
2025 · fourth_quarter · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.
Client expense: — · Firm income: $50,000
Matched citations: S. 2561
Skin Substitute Access and Payment Reform Act of 2025
2025 · third_quarter · Firm: THE MCMANUS GROUP
Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Issues related to skin substitute payment in 2026 Physician Fee Schedule Proposed Rule (CMS-1832-P). Skin Substitute Access and Payment Reform Act of 2025 (S. 2561).
Client expense: — · Firm income: $40,000
Matched citations: S. 2561
Source: Senate LDA